Academic Rank:
Professor, Dept of Pathology & Laboratory Medicine
Chief Medical & Scientific Officer, Canadian Blood Services
Affiliation(s):
Centre for Blood Research
Location:
Centre for Blood Research, Life Sciences Centre

Short Bio:

Dana Devine is currently the Chief Medical & Scientific Officer at Canadian Blood Services. She is also Professor of Pathology and Laboratory Medicine at the University of British Columbia, and a founding member of the University’s Centre for Blood Research. She is the Editor-in-Chief of the blood transfusion journal Vox Sanguinis. Dr. Devine completed her research training at Duke University in North Carolina where she obtained the Ph.D. degree. She has a longstanding research career in blood products, transfusion medicine, platelet biology, complement biochemistry, and coagulation.

Academic Backgrounds:
  • PhD (Immunology), Duke University, 1986
  • MA (Biology), Boston University, 1981
  • BA (Biology), Boston University, 1978
Selected Publications
  • Serrano K, Chen D, Hansen AL, Levin E, Turner TR, Kurach JD, Acker JP, Devine DV.. (2014). The effect of timing of gamma-irradiation on hemolysis and potassium release in leukoreduced red cell concentrates stored in SAGM.. Vox Sanguinis. 106(4): 379-81.
  • Lozano M, Mahon A, van der Meer PF, Stanworth S, Cid J, Devine D, Fung MK, de la Salle B, Heddle NM; Biomedical Excellence for Safer Transfusion (BEST) Collaborative.. (2014). Counting platelets at transfusion threshold levels: Impact on the decision to transfuse.. Vox Sanguinis. 106(4): 330-6.
  • Prudent M, D’Alessandro A, Cazenave JP, Devine DV, Gachet C, Greinacher A, Lion N, Schubert P, Steil L, Thiele T, Tissot JD, Völker U, Zolla L. (2014). Proteome changes in platelets after pathogen inactivation – an interlaboratory consensus. Transfusion Medicine Reviews. 28(2): 72-83.
  • Lozano M, Mahon A, van der Meer PF, Stanworth S, Cid J, Devine D, Fung MK, de la Salle B, Heddle NM; on behalf of Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Counting platelets at transfusion threshold levels: impact on the decision to transfuse. A BEST Collaborative – UK NEQAS(H) International Exercise. Vox Sang. 2013 Dec 12. doi: 10.1111/vox.12110. [Epub ahead of print].
  • Williamson LM, Devine DV. Challenges in the management of the blood supply. Lancet. 2013 May 25;381(9880):1866-75.
  • Schubert P, Coupland D, Culibrk B, Goodrich RP, Devine DV. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion. 2013 Dec;53(12):3164-73.
  • Reesink HW, Davis K, Wong J, Schwartz DW, Mayr WR, Devine DV, Georgsen J, Chiaroni J, Ferrera V, Roubinet F, Lin CK, O’Donovan B, Fitzgerald JM, Raspollini E, Villa S, Rebulla P, Makino S, Gounder D, Säfwenberg J, Murphy MF, Staves J, Milkins C, Mercado TC, Illoh OC, Panzer S. The use of the electronic (computer) cross-match. Vox Sang. 2013 May;104(4):350-64.
  • Levin E, Serrano K, Devine DV. Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Standardization of CD62P measurement: results of an international comparative study. Vox Sang. 2013 Jul;105(1):38-46.
  • Schubert P, Culibrk B, Karwal S, Slicher SJ, Devine DV. Optimization of platelet concentrate quality: Application of proteomic technologies to donor management. J. Proteomics 2012; 76:329–336.
Research:

The general subject areas of research expertise of this laboratory are platelet biology, complement biochemistry and blood coagulation. Our particular experimental focus in transfusion medicine is in the area of blood product processing and storage. Ongoing research projects include studies of the storage lesion of platelet concentrates and methods to improve the quality of stored platelet concentrates. Most recently, we have sought to apply leading edge technology to these research questions, in particular through the application of proteomics technology to investigations of blood products.The research in the laboratory also includes a significant component of applied development work with projects related to practical solutions to issues arising in the manufacture of blood products including process control and quality enhancement through modification of production processes or through understanding more about the significance of the variability of donor characteristics. We have ongoing collaborations with other scientists in all of these areas as well as collaborations with companies working in the blood transfusion business.